Current Report Filing (8-k)
25 April 2016 - 2:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 25, 2016
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
|
Framingham, Massachusetts
|
|
01702
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
On April 25, 2016, Arch Therapeutics, Inc. (the “
Company
”)
issued a press release announcing that the Company has received a notice of allowance from the U.S. Patent Office on a broad method
of use patent that covers systemically administering the Company’s self-assembling technology for treating damaged extracellular
matrix and leaky tight junctions. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference
herein.
|
Item 9.01
|
Financial Statements and Exhibit
|
|
Exhibit
|
|
Description
|
|
99.1
|
|
Press Release issued by Arch Therapeutics, Inc. on April 25, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
Dated: April 25, 2016
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Name: Terrence W. Norchi, M.D.
|
|
|
Title: President, Chief Executive Officer
|
|
|
|
|
|
Exhibit
List
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued by Arch Therapeutics, Inc. on April 25, 2016
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Arch Therapeutics Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere Arch Therapeutics, Inc. News-Artikel